KNect365 is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Zai Lab on regulatory reforms and effective partnering in China

Being a Shanghai-based biotech centered on in-licensing, Zai Lab has been successful in attracting foreign innovative assets and developing them domestically in China. One recent deal is with Five Prime Therapeutics for its FPA144, an immune therapy targeting gastric cancer patients with FGFR2b mutation in China.
Zai Lab's VP and Head of Business Development Jonathan Wang tells Brain Yang how China FDA's regulatory reforms make China attractive to international biotech, and discusses therapeutic areas which benefit such as oncology and anti-infectious treatment, and partnering in China.
The interview was conducted at China Showcase ahead of Biotech Showcase and JP Morgan Global Healthcare Conference.

Get the latest news as it happens.